A re-analysis of "failed" non-invasive prenatal tests based on whole-genome sequence data revealed hundreds of rare autosomal trisomies.
Natera saw total Q4 2016 revenues decline to $49.3 million, despite an increase in testing volumes.
The firm reported $3.5 million in revenue for the three months ended Dec. 31, 2016, and $12.9 million for the full year.
The firm has seen a small handful of false positives for the test in thousands of samples run since the study, but attributed them to biological features.
The G-BA commissioned a contractor to prepare an evidence report by early 2018 and to gather information for patients by early 2019.
The firm plans to include seven subchromosomal alterations to its NIPT by the end of March and wants to expand into the liquid biopsy market.
Starting Feb. 15, Aetna members will be able to access NxGen MDx's genetic screening and noninvasive prenatal testing as an in-network benefit.
Going forward, Natera said it will market its Panorama NIPT assay and carrier screening test Horizon directly to physicians.
The investment bank set a price target of $18.00 for shares of the molecular diagnostics company.
The organization will promote public awareness of cfDNA-based NIPT, encourage legislation supporting testing, and push for reimbursement policy changes.
An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.
Research funding in Canada is to remain mostly the same, ScienceInsider reports.
In Science this week: random DNA replication errors play role in cancer, and more.
The Bill and Melinda Gates Foundation embarks on an open-access publishing path.